felodipine has been researched along with Vasculitis in 1 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Vasculitis: Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metabolic syndrome is associated with an increased incidence of atherosclerosis." | 5.35 | Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. ( Bi, XP; Gong, HP; Li, L; Tan, HW; Xing, SS; Zhang, W; Zhang, Y; Zhong, M, 2008) |
| "Metabolic syndrome is associated with an increased incidence of atherosclerosis." | 1.35 | Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. ( Bi, XP; Gong, HP; Li, L; Tan, HW; Xing, SS; Zhang, W; Zhang, Y; Zhong, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, HW | 1 |
| Xing, SS | 1 |
| Bi, XP | 1 |
| Li, L | 1 |
| Gong, HP | 1 |
| Zhong, M | 1 |
| Zhang, Y | 1 |
| Zhang, W | 1 |
1 other study available for felodipine and Vasculitis
| Article | Year |
|---|---|
Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation.
Topics: Animals; Biotransformation; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cell Adhesion M | 2008 |